Hyloris Pharmaceuticals S.A. (0AB6) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Hyloris Pharmaceuticals S.A. €0.47, price €4.20, upside -88.8%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Hyloris Pharmaceuticals S.A. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
53‑month range €3.86 – €17.14 · fair‑value band €0.3100 – €0.5800 · the €4.20 price screens above the €0.4700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Hyloris Pharmaceuticals in your weekly email
Every Wednesday you see whether Hyloris Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific.
Show more
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections. It also provides Atomoxetine oral liquid for the treatment of attention deficit hyperactivity disorder; XTRAZA and Tranexamic Acid IV RTU for the prevention and treatment of excessive bleeding; HY-094 Iron IV to treat iron deficiency; and Pantoprazole IV for short-term treatment of adult patients with gastroesophageal reflux disease and a history of erosive esophagitis. In addition, the company is involved in the development of Alenura for painful bladder syndrome; Phosphate oral liquid for phosphate supplementation; and HY-095 PPI for the treatment of gastric ulcers in horses. Further, it develops Aspirin IV for acute coronary syndrome indication; Milrinone for late-stage HF with LVAD; Dofetilide IV for atrial fibrillation indication; HY-074 for acute coronary syndrome indication; Metolazone IV for congestive heart failure indication; and HY-75 for coronary heart disease indication. The company has collaboration agreements with FHP BV, Pleco Therapeutics, Vaneltix Pharma, Inc., and AFT Pharmaceuticals. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.
Stock analysis
Hyloris Pharmaceuticals S.A. (0AB6) currently trades at €4.20, while our model-based Fair Value estimate is €0.4700, 88.8% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: €0.3100 (bear) to €0.5800 (bull), the price of €4.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Industrials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Hyloris Pharmaceuticals S.A. reported revenue of €7.2M in FY2025 versus €3.1M in FY2021, a compound +23.5%/yr. Reported net income was −€6.3M in FY2025.
Key figures
Market cap €152M · P/S ratio 19.2 · EPS (TTM) €−0.4500 · Net margin −87.9% · Return on equity −21.6% · Return on assets (EBIT) −21.0% · Operating margin −101% · Revenue (TTM) €7.9M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −40% fair-value upside, at −89%, 0AB6 screens richer than that median.
Fair Value models
Bear €0.3100Fair Value €0.4700Bull €0.5800
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−14.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+110.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+107.2%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,186.9% (2020) → −107.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Hyloris Pharmaceuticals S.A. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 53 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−88.8% · Bottom 25%
Profitability
Return on assets−13.6% · Bottom 25%
Net margin (TTM)−79.8% · Bottom 25%
Operating margin (TTM)−100.5% · Bottom 25%
Growth and dividend
Revenue growth−10.2% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
P/B6.47× · Priciest 25%
P/S (TTM)21.58× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)0· sector 55
PAST (return on equity)0· sector 14
HEALTH (low debt)99· sector 98
DIVIDEND (yield)0· sector 24
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Hyloris Pharmaceuticals S.A. (0AB6) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €0.4700 versus a price of €4.20, about −89% upside (overvalued).
What is the fair value of 0AB6?
Our model-based fair value for Hyloris Pharmaceuticals S.A. is €0.4700 (as of Sep 24, 2026), built from audited fundamentals. The current price: €4.20.
What is the quality score of 0AB6?
Hyloris Pharmaceuticals S.A. has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hyloris Pharmaceuticals S.A. (0AB6)?
Our model-based price target is the fair value of €0.4700 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario €0.3100, optimistic scenario €0.5800. It is a calculation from audited fundamentals, not an analyst target.
What is the Hyloris Pharmaceuticals S.A. stock forecast for 2026?
Our models put fair value at €0.4700, about −89% upside versus a price of €4.20 (overvalued). Cautious scenario €0.3100, optimistic scenario €0.5800. The calculation is refreshed regularly with new filings.
What is the revenue of Hyloris Pharmaceuticals S.A. (0AB6)?
Hyloris Pharmaceuticals S.A. reported trailing-twelve-month revenue of about €7.9M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Hyloris Pharmaceuticals S.A. (0AB6)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hyloris Pharmaceuticals S.A. it is €0.4700 per share (as of Sep 24, 2026), against a price of €4.20. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Hyloris Pharmaceuticals S.A. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0AB6 trades above its calculated fair value: price €4.20, fair value €0.4700, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0AB6?
No. The price is what the market pays today (€4.20); the fair value is what the company's own numbers justify (€0.4700). For Hyloris Pharmaceuticals S.A. the two are €3.73 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hyloris Pharmaceuticals S.A. worth?
The market values Hyloris Pharmaceuticals S.A. at about €152M (market capitalisation, as of Sep 24, 2026). Per share that is €4.20; our models calculate a fair value of €0.4700 per share.
What do the bullish and bearish scenarios say about 0AB6?
Our models span a range for Hyloris Pharmaceuticals S.A.: cautious scenario €0.3100, base €0.4700, optimistic €0.5800 per share (as of Sep 24, 2026, price €4.20). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hyloris Pharmaceuticals S.A. (0AB6)?
Balance-sheet figures for Hyloris Pharmaceuticals S.A. (as of Sep 24, 2026): return on equity −21.6%, debt of 0.01 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 0AB6 from its 52-week high?
Hyloris Pharmaceuticals S.A. trades at €4.20, about 49% below its 52-week high of €8.22 and 2% above the low of €4.10 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of €0.4700 is for.
Which stocks are comparable to Hyloris Pharmaceuticals S.A.?
From the same area (Industrials) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hyloris Pharmaceuticals S.A. stock attractive at the current price?
The data as of Sep 24, 2026: price €4.20, calculated fair value €0.4700 (−89%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0AB6 calculated?
We run Hyloris Pharmaceuticals S.A. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.4700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Hyloris Pharmaceuticals S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hyloris Pharmaceuticals S.A. (0AB6)?
The closing price on Oct 1, 2026 was €4.20. Our model-based fair value is €0.4700, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hyloris Pharmaceuticals S.A. right now?
The price sits above even our optimistic bull case (€0.5800). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€0.3100 to €0.5800) leaves room in how you read the outcome.
Key figures of Hyloris Pharmaceuticals S.A.
How large is the market capitalisation of Hyloris Pharmaceuticals S.A. (0AB6)?
The market capitalisation of Hyloris Pharmaceuticals S.A. is €152M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hyloris Pharmaceuticals S.A. (0AB6)?
The price-to-sales ratio of Hyloris Pharmaceuticals S.A. is 19.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hyloris Pharmaceuticals S.A. (0AB6)?
Earnings per share at Hyloris Pharmaceuticals S.A. are €−0.4500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hyloris Pharmaceuticals S.A. (0AB6)?
The net margin of Hyloris Pharmaceuticals S.A. is −87.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hyloris Pharmaceuticals S.A. (0AB6)?
The return on equity (ROE) of Hyloris Pharmaceuticals S.A. is −21.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hyloris Pharmaceuticals S.A. (0AB6)?
On an EBIT basis the return on assets of Hyloris Pharmaceuticals S.A. is −21.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hyloris Pharmaceuticals S.A. (0AB6)?
The operating margin of Hyloris Pharmaceuticals S.A. is −101% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hyloris Pharmaceuticals S.A. (0AB6)?
Revenue at Hyloris Pharmaceuticals S.A. is growing −10.2% versus a year earlier (3y avg +34.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hyloris Pharmaceuticals S.A. (0AB6) generate?
The free cash flow of Hyloris Pharmaceuticals S.A. is −€7.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hyloris Pharmaceuticals S.A. (0AB6) carry?
The net debt of Hyloris Pharmaceuticals S.A. is €12.9M (fiscal year 2019). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hyloris Pharmaceuticals S.A. in the live analysis
One click puts Hyloris Pharmaceuticals S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
